Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Bronchopulmonary Dysplasia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04062136 |
Recruitment Status : Unknown
Verified August 2019 by Vinmec Research Institute of Stem Cell and Gene Technology.
Recruitment status was: Recruiting
First Posted : August 20, 2019
Last Update Posted : August 20, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Bronchopulmonary Dysplasia | Combination Product: stem cell transplantation | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 10 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Outcomes of Human Umbilical Cord-derived Mesenchymal Stem Cells Transplantation in the Treatment of Bronchopulmonary Dysplasia |
Actual Study Start Date : | March 1, 2019 |
Estimated Primary Completion Date : | November 30, 2020 |
Estimated Study Completion Date : | November 30, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Stem cell transplantation
1 million umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 1 week after the first transplantation
|
Combination Product: stem cell transplantation
Transplantation of umbilical cord mesenchymal stem cells |
- Adverse events and serious adverse events [ Time Frame: during 9 months post treatment ]Incidence of the adverse events or serious adverse events after transplantation
- The proportion of patients win from oxygen [ Time Frame: during 9 months post treatment ]To identify the proportion of patient with Bronchopulmonary Dysplasia win from oxygen after stem cell transplantation.
- The lung fibrosis [ Time Frame: at 6 months post treatment ]Changes of the lung fibrosis on chest CT at 6 months compared with baseline

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Month to 6 Months (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- The patient is diagnosis Bronchopulmonary Dysplasia (premature and depends on oxygen until 28 days old
- Gender: either sex
- Year old < 6 months
- Weight ≥ 2 kg
- Agree to participate in the study.
Exclusion Criteria:
- Severe congenital malformation.
- Other severe conditions (active pulmonary bleeding, evidence of active infections).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04062136
Contact: Liem T Nguyen, MD., PhD | (+844)39743556 ext 1420 | v.liemnt@vinmec.com | |
Contact: Thai H Trieu Thi, MD | (+8424) 3974 3556 | v.thaitth@vinmec.com |
Vietnam | |
Vinmec Research Institute of Stem Cell and Gene Technology | Recruiting |
Hanoi, Vietnam, 100000 | |
Contact: Liem T Nguyen, MD., PhD (+844)39743556 ext 1420 v.liemnt@vinmec.com | |
Vinmec Research Institute of Stem Cell and Gene Technology | Recruiting |
Hanoi, Vietnam, 100000 | |
Contact: Nguyen Thanh Liem, Prof |
Responsible Party: | Vinmec Research Institute of Stem Cell and Gene Technology |
ClinicalTrials.gov Identifier: | NCT04062136 |
Other Study ID Numbers: |
VinmecISC1915 |
First Posted: | August 20, 2019 Key Record Dates |
Last Update Posted: | August 20, 2019 |
Last Verified: | August 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Bronchopulmonary dysplasia umbilical cord mesenchymal stem cells |
Bronchopulmonary Dysplasia Hyperplasia Pathologic Processes Ventilator-Induced Lung Injury Lung Injury |
Lung Diseases Respiratory Tract Diseases Infant, Premature, Diseases Infant, Newborn, Diseases |